CONMED

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States, Americas excluding the United States, Europe, Middle East, and Africa, and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CONMED faces Q4 challenges, eyes growth through margin improvement

CONMED faced challenges in Q4 due to software implementation issues, resulting in revenue delays and lost opportunities.
Despite this, the company aims for revenue growth and margin improvement, with positive signs in sales recovery and operational stability.
2023 financial guidance shows optimism for growth, with a focus on cost reduction, salesforce retention, and new acquisitions.
Efforts to enhance gross margins and normalize operations present opportunities for profitability and market expansion in the coming years.

CONMED reports strong Q1 performance, focuses on innovation and advocacy

CONMED's Q1 2023 showcased robust sales growth and strategic acquisitions, despite challenges.
The company's focus on innovation, customer recovery, and advocacy positions it well for future success.
Resolving warehouse issues and adapting to potential legislation are key priorities for sustained growth.
Maintaining strong performance amidst challenges highlights CONMED's resilience and market positioning.

CONMED reports robust Q2 growth, eyes market expansion opportunities

CONMED's Q2 performance reflects strong sales growth and improved profitability, particularly in international markets.
The company faces challenges in convincing health systems to adopt pricier procedures and transitioning its sales focus.
Opportunities lie in demonstrating product value, expanding market share, and investing in growth areas like In2Bones and BioBrace.
Overall, CONMED's strategic focus on innovation and market expansion positions it for continued success in the medical device industry.

CONMED reports solid Q3 earnings, anticipates growth despite challenges

CONMED's Q3 performance showed growth in sales and adjusted net income, despite facing supply constraints. The company remains optimistic about future organic growth and expects improvements in margins and FX impact for 2024. Financial stability and strong product performance position CONMED well for future growth.

CONMED reports record revenue in Q4, eyes growth amid challenges

CONMED delivered strong financial performance in Q4 2023, with robust revenue growth and margin improvement, setting optimistic revenue guidance for 2024.
Strategic acquisitions and focus on profitability highlight CONMED's strengths, while challenges like supply disruptions and market dynamics require careful navigation.
Opportunities lie in M&A prospects, BioBrace's growth potential, and differentiation strategies, positioning CONMED for continued success in the medical devices market.

CONMED posts robust Q1 results, adjusts guidance amidst currency impact

CONMED's Q1 results reflect strong financial performance, operational improvements, and strategic leadership changes, setting a positive tone for future growth.
While facing challenges such as currency impacts and guidance adjustments, the company's resilience and commitment to growth remain evident in its revised projections.
With a focus on operational efficiency, market expansion, and maintaining growth momentum, CONMED is poised to navigate challenges and leverage opportunities for sustained success.

CONMED reports Q2 growth, faces Orthopedic supply challenges

CONMED's Q2 performance showed overall growth, with notable strength in the general surgery segment.
Challenges in the Orthopedic side impacted sales and guidance for the year.
The company's focus on cost management and margin improvement is evident in the financial results.
Balancing supply chain issues while capitalizing on general surgery opportunities will be key moving forward.

CONMED reports strong Q3 earnings amidst leadership transition and challenges

CONMED's Q3 performance reflects a resilient financial standing and strategic leadership transition, setting the stage for continued growth.
While challenges like hurricane impacts and supply chain disruptions persist, CONMED's strengths in key segments provide a foundation for future success.
The company's focus on operational efficiency, growth opportunities, and leadership continuity positions CONMED well for sustainable profitability and market expansion.
Navigating challenges and capitalizing on growth opportunities will be crucial for CONMED to drive innovation and maintain its competitive edge in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Conmed (CNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Conmed (CNMD) a New Buy Stock

News for CONMED Stock (CNMD)